Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab for Intestinal aGvHD Prophylaxis in Allo-HSCT
NCT03657160Phase 3Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Feb 2019
- Primary completion
- Feb 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in Acute Graft-Versus-Host Disease (aGvHD) comparing Vedolizumab with Placebo (2 arms). Primary endpoint: Intestinal Acute Graft-Versus-Host Disease-Free Survival. Started Feb 2019; status: completed.
02
Drugs
vedolizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT03657160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03657160.